The pharmaceutical sector continues to attract income-focused investors, with Merck (MRK) and Novartis (NVS) standing out as top dividend stocks. Both companies boast robust product portfolios and pipelines, having outperformed the S&P 500 over the past year. However, the competitive landscape and patent expirations present unique challenges for each firm, influencing their investment appeal.

Merck faces potential sales declines as its leading oncology drug, Keytruda, approaches patent expiration, despite recent approvals for new formulations. In contrast, Novartis has adeptly managed the loss of exclusivity for its heart failure treatment, Entresto, while maintaining strong sales growth across its diverse product lineup. Novartis also offers a slightly higher dividend yield and a more consistent payout history, making it a safer bet for long-term income investors.

For those seeking stability in the pharmaceutical space, Novartis emerges as the preferable choice, combining a solid dividend yield with a diversified portfolio that mitigates risks associated with patent expirations.

Source: fool.com